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Abstract
To better understand the means by which cells such as human platelets regulate the binding of the integrin KIIbL3 to
fibrinogen, we have examined agonist-initiated inside-out and outside-in signalling in CHRF-288 cells, a megakaryoblastic
cell line that expresses KIIbL3 and the human thrombin receptor, PAR1. The results show several notable similarities and
differences. (1) Activation of PAR1 caused CHRF-288 cells to adhere and spread on immobilized fibrinogen in an KIIbL3-
dependent manner, but did not support the binding of soluble fibrinogen or PAC-1, an antibody specific for activated KIIbL3.
(2) Direct activation of protein kinase C with PMA or disruption of the actin cytoskeleton with low concentrations of
cytochalasin D also caused CHRF-288 cells to adhere to fibrinogen. (3) Despite the failure to bind soluble fibrinogen,
activation of PAR1 in CHRF-288 cells caused phosphoinositide hydrolysis, arachidonate mobilization and the
phosphorylation of p42MAPK, phospholipase A2 and the Rac exchange protein, Vav, all of which occur in platelets.
PAR1 activation also caused an increase in cytosolic Ca2, which, when prevented, blocked adhesion to fibrinogen.
(4) Finally, as in platelets, adhesion of CHRF-288 cells to fibrinogen was followed by a burst of integrin-dependent (‘outside-
in’) signalling, marked by FAK phosphorylation and a more prolonged phosphorylation of p42MAPK. However, in contrast
to platelets, adhesion to fibrinogen had no effect on Vav phosphorylation. Collectively, these observations show that
signalling initiated through PAR1 in CHRF-288 cells can support KIIbL3 binding to immobilized ligand, but not the full
integrin activation needed to bind soluble ligand. This would suggest that there has been an increase in integrin avidity
without an accompanying increase in affinity. Such increases in avidity are thought to be due to integrin clustering, which
would also explain the results obtained with cytochalasin D. The failure of KIIbL3 to achieve the high affinity state in CHRF-
288 cells was not due to the failure of PAR1 activation to initiate a number of signalling events that normally accompany
platelet activation nor did it prevent at least some forms of outside-in signalling. However, at least one marker of outside-in
signalling, the augmentation of Vav phosphorylation seen during platelet aggregation, did not occur in CHRF-288
cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The binding of integrins to their cognate ligands is
often the outcome of agonist-initiated intracellular
events, particularly in cells such as platelets that
are normally not adherent. In the case of platelets,
the ability of plasma ¢brinogen to bind to the integ-
rin KIIbL3 following platelet activation is a prerequi-
site for aggregation, but the signalling pathways that
enable KIIbL3 to become a high a⁄nity ¢brinogen
binding site are still under investigation. Pathways
leading to integrin activation are commonly referred
to as inside-out signalling to distinguish them from
the integrin-dependent intracellular events triggered
by integrin engagement, termed outside-in signalling.
This sequence of inside-out and outside-in signals is
not limited to KIIbL3, nor is it exclusively hierarchical
since outside-in signalling can clearly a¡ect events
downstream from activated receptors [1^3].
Although platelets and megakaryocytes are the
only normal cells that express KIIbL3, several mega-
karyoblastic and tumor cell lines also express KIIbL3
and heterologous expression of the integrin in CHO
cells (e.g. [4,5]) and lymphocytes [6,7] has been used
to create model systems for studying integrin activa-
tion. There are di¡erences, however, between the be-
havior of the integrin in platelets and in other cells.
The addition of an agonist to platelets allows KIIbL3
to bind to either soluble or immobilized ¢brinogen
and is accompanied by conformational changes in
the integrin that can be detected by antibodies such
as PAC-1 [8]. Megakaryoblastic cell lines on the oth-
er hand typically bind neither ¢brinogen nor PAC-1
unless the proteins are ¢rst immobilized on a solid
surface, at least when the cells are activated with
phorbol myristate acetate (PMA), which is the stim-
ulus that has been studied most [9,10]. The inability
of these cells to bind to soluble ¢brinogen when
stimulated with PMA suggests that protein kinase
C (PKC) activation can produce only an increase
in KIIbL3 avidity and not an increase in a⁄nity
such as occurs in agonist-stimulated platelets [9].
The increase in avidity is thought to be due to the
clustering of KIIbL3 at points of contact between the
cells and the ¢brinogen-coated surface, enabling ad-
hesion through the accumulation of low a⁄nity
binding sites even though the high a⁄nity state of the
integrin needed for binding to soluble ligand has not
been achieved (reviewed in [11] and [12]). The
response of KIIbL3 in the megakaryoblastic cell lines
to biologically important agonists such as throm-
bin is less well-explored, as is the role of PKC
when adhesion is initiated by agonists other than
PMA.
Potential explanations for the failure of KIIbL3 to
bind to soluble ¢brinogen or PAC-1 in cells other
than platelets (and megakaryocytes) include the ab-
sence of essential accessory molecules and the failure
of one or more key inside-out signalling pathways. In
either case, comparisons between platelets and other
cells that express KIIbL3 continue to provide one of
the principal means to understand agonist-induced
integrin activation. In the present studies, we have
made such a comparison, focusing on the inside-
out and outside-in signalling events initiated by acti-
vating thrombin receptors in the human megakaryo-
blastic CHRF-288 cell line. CHRF-288 cells nor-
mally express KIIbL3 [13] and PAR1 [14], the
predominant thrombin receptor expressed on human
platelets. PAR1 is a G protein-coupled receptor that
is activated by proteolytic cleavage of its N-terminus,
exposing a tethered ligand [15]. Thrombin activates
PAR1, as do peptides mimicking the exposed ligand
(SFLLRN). In contrast to PMA, which is a weak
stimulus for platelet aggregation in the absence of
other agonists [16,17], thrombin and SFLLRN are
full agonists, causing both aggregation and secretion.
This di¡erence suggests that the PAR1 agonists are
doing more to produce ¢brinogen receptor exposure
in platelets than just activating PKC.
To better understand the relationship between
PAR1 activation and KIIbL3 engagement, we asked
the following three questions. First, will PAR1 acti-
vation in CHRF-288 cells support high a⁄nity
KIIbL3-dependent binding to soluble ligands or just
to immobilized proteins? Second, are the signalling
pathways required for each of these events to occur
the same in CHRF-288 cells as they are in platelets?
Third, is the adhesion of CHRF-288 cells to immo-
bilized ¢brinogen su⁄cient to support outside-in sig-
nalling and, if so, are the consequences of that sig-
nalling the same as in platelets?
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2. Materials and methods
2.1. Materials
Human K-thrombin was a gift from Dr John Fen-
ton (New York State Department of Health, Albany,
NY, USA). The thrombin receptor agonist peptide,
SFLLRN, was synthesized by the Protein and Nu-
cleic Acid Core Facility of Children’s Hospital of
Pennsylvania, puri¢ed by high pressure liquid chro-
matography and con¢rmed by amino acid analysis
and protein sequencing. Anti-phosphotyrosine
monoclonal antibodies 4G10 and PY20 were ob-
tained from Dr Tom Roberts (Dana Farber Cancer
Institute, Boston, MA, USA) and ICN Biochemicals
(Irvine, CA, USA), respectively. Bovine serum albu-
min (BSA) for immunoblots was also obtained from
ICN Biochemicals. Human ¢brinogen was obtained
from Kabi (distributed by Helena Laboratories,
Beaumont, TX, USA). Fab fragments of the anti-
KIIbL3 monoclonal antibody 7E3 were provided by
Dr Barry Coller (Mt. Sinai Hospital, New York,
NY, USA) and Dr Robert Jordan (Centacor). The
anti-KIIbL3 monoclonal antibodies A2A9 and PAC-1
were supplied by Drs Joel Bennett (University of
Pennsylvania) and Sanford Shattil (Scripps Institute,
La Jolla, CA, USA). Fab fragments of the LIBS6
antibody were provided by Dr Mark Ginsberg
(Scripps Institute). A rabbit polyclonal antiserum di-
rected against residues 577^590 of Vav was provided
by Drs Xose¤ Bustelo and Mariano Barbacid (Bristol-
Meyers Squibb). The anti-FAK antibody, BC3, was
obtained from Dr Tom Parsons (University of Vir-
ginia). CHRF-288 cells were a gift from Dr M. Lie-
berman (University of Cincinnati College of Medi-
cine, Cincinnati, OH, USA). Bisindolylmaleimide-I
(Bis-IM) was obtained from CalBiochem (San Die-
go). Cytochalasin D was obtained from Sigma.
2.2. Adhesion
CHRF-288 cells were washed and resuspended in
serum-free RPMI 1640 medium with 1% BSA for 4 h
or overnight at a concentration of 5U106 cells/ml.
Incubations were performed in untreated 35 mm
dishes (Falcon or Nunc) that were coated overnight
with 100 Wg/ml ¢brinogen and then washed with
phosphate-bu¡ered saline (PBS), blocked with 5
mg/ml BSA for 30 min and washed four times with
PBS containing Ca2 and Mg2. Non-adherent cells
were removed by washing with PBS containing Ca2
and Mg2. To quantitate adhesion, CHRF-288 cells
were labelled overnight with [35S]methionine and
then serum-starved for 4 h prior to the start of the
experiment. After removing non-adherent cells, the
remaining adherent cells were lysed with RIPA bu¡er
(1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 158 mM NaCl, 10 mM Tris (pH 7.2), 1 mM
EGTA, 1 mM phenylmethylsulfonyl£uoride, 1.0 mM
Na3VO4 and aprotinin at 100 U/ml) and 35S was
measured. Adhesion was also measured colorimetri-
cally by lysing the cells in 0.6 ml 0.1 M citrate bu¡er,
pH 5.4, with 0.1% Triton X-100 and 2.33 mg/ml p-
nitrophenyl phosphate. The reaction was stopped
after 30 min by adding 0.3 ml 2 M NaOH and the
OD405 was recorded.
2.3. Flow cytometry
CHRF-288 cells were resuspended in RPMI 1640
medium with 10% fetal calf serum at a ¢nal concen-
tration of 3U106 cells/ml and then incubated for 15
min at room temperature or 37‡C with thrombin or
PMA and a FITC-conjugated antibody. Analysis
was performed on a Becton Dickinson (Mountain
View, CA, USA) FACScan.
2.4. Lysate preparation and immunoprecipitation
Adherent CHRF-288 cells were lysed as described
above. Non-adherent cells present in the media were
also sedimented at 3000Ug for 1 min, lysed with 500
Wl RIPA bu¡er and combined with the lysate from
the adherent cells in order to examine proteins from
the entire cell population and to maintain consis-
tency with samples prepared from cells plated on
BSA. Lysates were normalized for protein levels be-
fore immunoprecipitation or electrophoresis. FAK
[18] and Vav [19] were precipitated as previously de-
scribed.
2.5. Immunoblotting
Standard 7.5% acrylamide gels were used for elec-
trophoresis. When examining a shift in electropho-
retic mobility, an acrylamide stock containing an
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acrylamide:bis ratio of 35:0.6% was used. Anti-phos-
photyrosine immunoblots were performed using a
mixture of 4G10 and PY20 antibodies. MAP kinase
immunoblots were performed using a monoclonal
antibody speci¢c for p42MAPK (ERK2), UBI. Cyto-
plasmic phospholipase A2 (cPLA2) immunoblots
were probed with a polyclonal anti-cPLA2 antibody
(Genetics Institute). Goat anti-mouse or anti-rabbit
immunoglobulin-horseradish peroxidase conjugated
antibodies (Bio-Rad Laboratories, Richmond, CA,
USA) and a chemiluminescence detection kit (Amer-
sham) were used for detection [20].
2.6. Cytosolic calcium
CHRF-288 cells were loaded with 5 WM Fura-2/
AM (Molecular Probes) in RPMI 1640 without Phe-
nol red for 1 h at 37‡C. The detached cells were then
washed, resuspended in RPMI 1640 without phenol
red, allowed to equilibrate 30 min at room temper-
ature, washed again and used at 1U106 cells/ml.
Changes in the cytosolic free Ca2 concentration
were measured with an SLM/Aminco model AB2
£uorescence spectrophotometer [21].
2.7. Arachidonate release
CHRF-288 cells were serum-starved overnight in
the presence of 0.5 WCi/ml [3H]arachidonic acid,
washed three times and resuspended at a ¢nal density
of 1.25U106 cells/ml. Cells were plated (0.8 ml/plate)
and lipids were extracted using Bligh/Dyer solvent
(2:1 methanol:chloroform). To ensure maximal re-
covery, media from plates were added to 2 ml of
a 1:1 solution of methanol:chloroform. The adherent
cells were scraped on ice into 1 ml of cold methanol
and the solutions were combined. Free [3H]arach-
idonic acid was quantitated by thin layer chromatog-
raphy [22], followed by scintillation counting of the
regions that co-migrated with arachidonic acid
standards.
3. Results
CHRF-288 cells normally grow in suspension, so
to start, we asked whether activation of PAR1 with
thrombin or the agonist peptide, SFLLRN, would
cause CHRF-288 cells to either bind soluble ¢brino-
gen and PAC-1 or adhere to immobilized ¢brinogen.
In Fig. 1, cells that were exposed to thrombin or
PMA were incubated with either A2A9 [23], a mono-
clonal antibody that binds to the resting as well as
the activated conformation of KIIbL3, or PAC-1 [8], a
monoclonal antibody that binds selectively to acti-
vated KIIbL3. In the absence of an agonist, the
CHRF-288 cells bound A2A9, but not PAC-1. There
was no increase in PAC-1 binding when the cells
were activated. The ability of CHRF-288 cells to
bind to soluble ¢brinogen was tested in two ways.
First, using £ow cytometry to detect the binding of
an anti-¢brinogen antibody to CHRF-288 cells after
they were incubated with ¢brinogen and, second, by
observing for visible aggregation when CHRF-288
cells were stirred in the presence of Ca2 and ¢bri-
nogen. In neither case did thrombin receptor activa-
tion appear to cause ¢brinogen binding (data not
shown).
To test for adhesion, serum-depleted CHRF-288
cells were incubated in dishes coated with either ¢-
brinogen or BSA. There was little adhesion to ¢bri-
nogen in the absence of an agonist or to BSA under
any circumstances, but cells stimulated with either
SFLLRN (Fig. 2) or PMA (Fig. 3A) rapidly adhered
to and spread on ¢brinogen (note that most of the
cells seen in Fig. 2A are neither adherent nor spread,
while those seen in Fig. 2B have done both). Adhe-
sion was half-maximal within 5 min (Fig. 2C) and
Fig. 1. Binding of anti-KIIbL3 antibodies to CHRF-288 cells.
CHRF-288 cells were incubated with PMA or thrombin as indi-
cated plus FITC-conjugated A2A9 or PAC-1. A2A9 is a com-
plex-speci¢c anti-KIIbL3 antibody that recognizes resting and ac-
tivated KIIbL3. PAC-1 is speci¢c for the activated form of
KIIbL3. The results shown are representatives of those obtained
in two experiments.
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could be inhibited by the anti-KIIbL3 antibody, 7E3,
and by an RGD-containing peptide (data not
shown).
Collectively, these results show that CHRF-288
cells will adhere to immobilized ¢brinogen in an
KIIbL3-dependent manner when activated via a G
protein-coupled receptor agonist. However, as has
been observed when other megakaryoblastic cell lines
were stimulated with PMA, the increase in integrin
avidity that is implied by adhesion to immobilized
¢brinogen is apparently not accompanied by the in-
crease in a⁄nity that is needed to bind soluble ¢bri-
nogen. Increased avidity is thought to be due to an
accumulation of relatively low a⁄nity interactions
between integrin and ligand, perhaps facilitated by
an agonist-induced increase in lateral mobility of
the integrin [9,24]. In keeping with that hypothesis,
we found that cytochalasin D, which disrupts the
actin cytoskeleton, was as e¡ective as SFLLRN
and PMA in causing the CHRF-288 cells to adhere
to ¢brinogen (Fig. 4). A similar result has been ob-
tained for KIIbL3 in platelets (J. Bennett et al., un-
published observation) and LFA-1 in EBV-trans-
formed B-cells [24]. In the latter case, it was shown
that concentrations similar to those that caused the
adhesion of CHRF-288 cells to ¢brinogen in the
present study caused an increased adhesion of the
lymphocytes to ICAM-1 and increased the mem-
brane mobility of LFA-1, while higher concentra-
tions inhibited adhesion [24]. We observed the same
concentration-dependent adhesion in CHRF-288
cells incubated with cytochalasin D.
C
Fig. 2. Adhesion of CHRF-288 cells to a ¢brinogen-coated sur-
face. CHRF-288 cells that were serum-starved overnight were
incubated for 25 min with 10 WM SFLLRN in plastic dishes
that were coated with either (A) BSA or (B) ¢brinogen. Note
that most of the cells in (A) have not adhered to the dish, while
those in (B) have both adhered and spread. (C) CHRF-288 cells
that were serum-starved overnight and radiolabelled with
[35S]methionine were incubated with 10 WM SFLLRN in a plas-
tic dish coated with either BSA or ¢brinogen. At each of the
times shown, non-adherent cells were removed and the adherent
cells were quantitated by scintillation counting. The results
shown are representatives of two such studies with each data
point determined in triplicate.
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3.1. Inside-out signalling pathways
Given that PAR1 activation in platelets allows
KIIbL3 to bind soluble ligands, while in CHRF-288
cells PAR1 activation supports only binding to im-
mobilized ligands, we next compared some of the
signalling events initiated by PAR1 agonists in
CHRF-288 cells with those that occur in platelets.
PAR1 activation in platelets stimulates phospholi-
pase C, leading to PKC activation and an increase
in cytosolic Ca2. This is also true in CHRF-288 cells
where thrombin and SFLLRN are known to stimu-
late inositol phosphate formation and cause a tran-
sient increase in the cytosolic Ca2 concentration to
0.5^1.0 WM [14]. In permeabilized platelets, pertussis
toxin inhibits phosphoinositide hydrolysis [25] and
PAC-1 binding [26]. In contrast, pre-incubating
CHRF-288 cells overnight with a high concentration
of pertussis toxin inhibited SFLLRN-induced phos-
phoinositide hydrolysis by 50% (not shown), but had
little e¡ect on adhesion in response to SFLLRN and
no e¡ect on adhesion in response to PMA (Fig. 3B).
This suggests that there may be di¡erences in the
repertoire of G proteins used for PAR1 signalling
Fig. 3. Adhesion of CHRF-288 cells : inside-out signaling. (A) CHRF-288 cells were allowed to adhere to a ¢brinogen-coated surface
either without stimulation or in the presence of SFLLRN, PMA or ionomycin at the concentrations shown. Non-adherent cells were
removed by washing and adherent cells were quantitated colorimetrically. The results are the mean þ S.E.M. from six studies expressed
as a % of the increase in optical density (OD) in the absence of the inhibitor after subtracting the baseline OD in the absence of ago-
nist. (B) The cells were pre-incubated overnight with 200 ng/ml pertussis toxin (n = 3). (C) The cells were pre-incubated with 10 WM
Bis-IM for 30 min before the addition of SFLLRN or PMA (n = 5). (D) CHRF-288 cells loaded with 25 WM BAPTA were incubated
with SFLLRN or PMA (n = 4).
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in the two types of cells, with pertussis toxin-insensi-
tive members of the Gq family playing a larger role
in coupling PAR1 to phospholipase C in CHRF-288
cells than in platelets.
The observation that PMA causes CHRF-288 cells
to adhere to ¢brinogen suggests that PKC could be
one of the mediators of PAR1-initiated adhesion. To
test this, CHRF-288 cells were pre-incubated with
the PKC inhibitor Bis-IM and then stimulated with
either SFLLRN or PMA. Bis-IM inhibited adhesion
in response to PMA by 90%, but had little e¡ect on
adhesion in response to SFLLRN (Fig. 3C), suggest-
ing that the PMA-sensitive, Bis-IM-inhibitable iso-
forms of PKC are not essential for adhesion follow-
ing PAR1 activation. This contrasts with results
obtained looking at the role of cytosolic Ca2. In-
creasing the cytosolic Ca2 concentration with the
Ca2 ionophore ionomycin mimicked the response
to SFLLRN. Loading the cells with the intracellular
Ca2 chelator BAPTA decreased adhesion in re-
sponse to both SFLLRN and PMA by s 90%
(Fig. 3A and D).
Collectively, these results suggest that an increase
in cytosolic Ca2 mediated by a pertussis toxin-in-
sensitive G protein is needed for PAR1 agonists to
cause adhesion. One of the better-described conse-
quences of the rise in cytosolic Ca2 in platelets is
the activation of phospholipase A2 and the forma-
tion of thromboxane A2 (TxA2) from arachidonic
acid. The released TxA2 contributes to platelet ag-
gregation by amplifying the e¡ects of the original
agonist. To determine whether phospholipase A2 is
turned on in CHRF-288 cells when PAR1 is acti-
vated, we measured the phosphorylation of cPLA2
[27,28] and release of [3H]arachidonate from mem-
brane phospholipids. cPLA2 phosphorylation was
detectable within 5 min of the addition of SFLLRN
and was sustained for at least 20 min (Fig. 5). Arach-
idonate release from radiolabelled CHRF-288 cells
was also maximal within 5 min and, like cPLA2
phosphorylation, occurred to the same extent
whether the cells were in suspension or were allowed
to adhere to ¢brinogen, a point that will be returned
to latter.
Fig. 4. Cytochalasin D causes CHRF-288 cells to adhere to ¢-
brinogen. CHRF-288 cells were incubated in a ¢brinogen-
coated dish for 30 min with SFLLRN, PMA or cytochalasin D
at the concentrations indicated. The results shown are represen-
tatives of two similar experiments.
Fig. 5. Phosphorylation of phospholipase A2 and release of
arachidonate. (A) CHRF-288 cells that were serum-starved
overnight were incubated with 10 WM SFLLRN in a dish
coated with either BSA or ¢brinogen. At each of the times
shown, lysates were prepared from all of the cells in the dish
(adherent and non-adherent) and equal amounts of protein
were subjected to gel electrophoresis and Western blotting with
antibodies that recognize cPLA2. The asterisk indicates the po-
sition of phosphorylated cPLA2. (B) CHRF-288 cells were la-
belled overnight with [3H]arachidonate and serum-starved the
following day for 4 h. Afterwards, the cells were incubated with
10 WM SFLLRN in dishes coated with either BSA or ¢brino-
gen. At the times indicated, phospholipids were extracted and
free [3H]arachidonate was measured. The results shown are typ-
ical of three such experiments performed in triplicate.
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3.2. PI 3-kinase activation and Vav phosphorylation
In platelets, PAR1 activation by thrombin or
SFLLRN also causes an increase in PI 3-kinase ac-
tivity and the accumulation of 3-phosphorylated
phosphoinositides [29]. CHRF-288 cells, like plate-
lets, contain the p85/p110 (growth factor-activated)
and p101/p110Q (GLQ -activated) forms of PI 3-kinase
[30]. Activation of these enzymes in platelets [31] and
CHRF-288 [30] cells has been shown to be sensitive
to wortmannin with an IC50 of 1^10 nM. At low
concentrations, neither wortmannin nor a second
PI 3-kinase inhibitor, LY294006, a¡ected the adhe-
sion of CHRF-288 cells to ¢brinogen in response to
SFLLRN (data not shown). Only when wortmannin
and LY294002 were added at much higher concen-
trations (100 nM and 50 WM), adhesion was inhibited
and even this inhibition could be overcome by in-
creasing the concentration of SFLLRN or PMA
(Fig. 6). This suggests that PAR1-initiated adhesion
of the CHRF-288 cells is not absolutely dependent
on PI 3-kinase activity. Notably, we obtained a sim-
ilar result with platelets. At 5 WM SFLLRN, wort-
mannin and LY294002 inhibited platelet aggrega-
tion, but at higher SFLLRN concentrations,
aggregation occurred despite the inhibitors (not
shown).
Finally, an additional response to PAR1 activation
in platelets is the phosphorylation of the 95 kDa
protein, Vav [19]. Vav is an exchange factor for
RhoA and Rac1 [32,33] and a substrate for the ty-
rosine kinases Lck [33], Syk [34] and ZAP-70 [34].
Vav phosphorylation in thrombin-stimulated plate-
lets is not inhibited by antagonists of platelet aggre-
gation such as the synthetic peptide Arg-Gly-Asp-Ser
(RGDS), but since vigorous Vav phosphorylation
also occurs when platelet adhesion to ¢brinogen is
forced by the anti-KIIbL3 antibody LIBS6, Vav is
potentially an intermediate in both outside-in and
inside-out signalling [19]. Vav is expressed in
CHRF-288 cells and became phosphorylated when
the cells were stimulated with SFLLRN (Fig. 7).
Phosphorylation was detectable within 5 min and,
like cPLA2 phosphorylation (Fig. 5), occurred to
the same extent whether or not the CHRF-288 cells
were allowed to adhere to ¢brinogen, an issue that
will be discussed further in the next section.
Fig. 6. Inhibition of PI 3-kinase. CHRF-288 cells were stimu-
lated with SFLLRN or PMA after pre-incubating the cells for
30 min with either wortmannin or LY294002. Adhesion to a ¢-
brinogen-coated surface was measured 30 min later (n = 2^4).
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3.3. Outside-in signalling
In platelets, the inside-out signalling that supports
KIIbL3 activation leads to integrin-dependent outside-
in signalling when signalling complexes form around
the integrin cytoplasmic domains [11]. Since CHRF-
288 cell KIIbL3 does not form high a⁄nity ¢brinogen
binding sites, it was unclear whether outside-in sig-
nalling would occur and would be the same or di¡er-
ent than in platelets. Two recognized markers were
used to detect outside-in signalling in PAR1-acti-
vated CHRF-288 cells: phosphorylation of the 125
kDa focal adhesion kinase, FAK, and sustained
phosphorylation of the serine/threonine kinase,
ERK2. CHRF-288 cells were incubated with
SFLLRN in dishes coated with ¢brinogen or BSA
and then lysed. FAK was precipitated and then
probed with an anti-phosphotyrosine antibody.
There was no detectable phosphorylation of FAK
in unstimulated cells or in cells incubated on BSA
(not shown), but in the ¢brinogen-coated dishes,
FAK became phosphorylated within 10 min, some-
what slower than the kinetics of adhesion (Fig. 8).
In the second approach, outside-in signalling was
detected using ERK2 phosphorylation as an end-
point. In cells that are chronically adherent, such
as ¢broblasts, integrin engagement enhances growth
factor-induced MAPK phosphorylation [1^3,35]. To
test whether this also occurs in CHRF-288 cells fol-
lowing PAR1 activation, the cells were incubated
with SFLLRN, lysed and then immunoblotted with
an anti-ERK2 antibody. Phosphorylation was de-
tected as a decrease in electrophoretic mobility and
occurred in both the adherent and the non-adherent
cells. However, while ERK2 phosphorylation was
undetectable after 5 min in cells plated on BSA, it
was sustained for at least 20 min in cells allowed to
adhere to ¢brinogen (Fig. 9A, right, and B, left).
Notably, although this result resembles those ob-
tained with chronically adherent cells, it is di¡erent
Fig. 9. MAP kinase activation in adherent and non-adherent
CHRF-288 cells. (A) CHRF-288 cells that were serum-starved
overnight were incubated with 10 WM SFLLRN in a dish
coated with either BSA or ¢brinogen. At each of the times
shown, lysates were prepared from all of the cells in the dish
(adherent and non-adherent) and equal amounts of protein
were subjected to gel electrophoresis and Western blotting with
antibodies that recognize ERK2. The asterisk indicates the posi-
tion of phosphorylated ERK2. (B) CHRF-288 cells that were
serum-starved overnight were incubated with 10 WM SFLLRN
or 100 Wg/ml LIBS6 Fab fragments in a dish coated with ¢bri-
nogen. At each of the times shown, lysates were prepared and
subjected to gel electrophoresis and Western blotting with anti-
bodies that recognize ERK2. The results shown are representa-
tives of at least two studies of each type.
Fig. 8. Phosphorylation of FAK. CHRF-288 cells that were se-
rum-starved overnight were incubated with 10 WM SFLLRN in
a dish coated with ¢brinogen. At each of the times shown, ly-
sates were prepared, FAK was immunoprecipitated and an
anti-phosphotyrosine blot was performed. The results shown
are representatives of two such studies.
Fig. 7. Phosphorylation of Vav in CHRF-288 cells. (A) Serum-
starved CHRF-288 cells were incubated with or without 10 WM
SFLLRN for 10 min in dishes coated with ¢brinogen. After lys-
ing the cells, Vav was immunoprecipitated with an anti-Vav
antibody and then immunoblotted with a phosphotyrosine anti-
body. Where indicated, the cells were pre-incubated with pertus-
sis toxin before stimulation with SFLLRN. (B) The same as
(A) except that the cells were incubated with SFLLRN in
dishes coated with ¢brinogen or BSA for the times indicated.
The results shown in this ¢gure are representatives of at least
two similar studies.
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than what has been reported in human platelets. In
platelets, activation of PAR1 causes ERK2 phos-
phorylation [36,37], but the extent of phosphoryla-
tion has been shown to decrease, rather than in-
crease, when the platelets are allowed to aggregate
[35].
Finally, to determine whether integrin engagement
and adhesion alone are su⁄cient to cause outside-in
signalling in CHRF-288 cells, the cells were incu-
bated with Fab fragments of the KIIbL3 antibody
LIBS6, in the absence of SFLLRN. LIBS6 binds to
the integrin L3 subunit, forcing a conformational
change that allows ¢brinogen to bind in the absence
of an agonist [38]. As already described, addition of
LIBS6 to platelets causes adhesion to ¢brinogen and
phosphorylation of Vav, even when the autocrine
and paracrine e¡ects of secreted agonists are elimi-
nated [19]. When added to CHRF-288 cells, LIBS6
caused most of the cells to adhere to ¢brinogen.
However, in contrast to SFLLRN, there was little
ERK2 phosphorylation during LIBS6-induced adhe-
sion (Fig. 9B, right). Therefore, these results suggest
that adhesion alone is insu⁄cient to trigger outside-
in signalling in CHRF-288 cells and that the en-
hancement in ERK2 phosphorylation observed
when SFLLRN-activated CHRF-288 cells adhere to
¢brinogen is not due to simple additivity.
4. Discussion
Integrins such as KIIbL3 appear to exist in at least
three states, an inactive ligand-free state, a fully ac-
tivated state in which high a⁄nity binding to soluble
ligands is possible and a low a⁄nity/high avidity
state which may be more attributable to integrin
clustering than to integrin activation in the usual
sense. The agonist-induced switch from an inactive
to an active conformation is particularly relevant for
platelets since ¢brinogen binding to KIIbL3 is essential
for platelet aggregation at sites of vascular injury.
Recent studies have focused on the identi¢cation of
signalling pathways and molecules that can interact
with integrin cytoplasmic domains and regulate in-
tegrin conformation from within. A number of such
molecules have been identi¢ed [39^42], but a com-
plete picture has yet to emerge. In the present stud-
ies, we examined the interaction of KIIbL3 with ¢bri-
nogen following thrombin receptor activation in
CHRF-288 cells. Previous work by other investiga-
tors has shown that other megakaryoblastic cell lines
will adhere to immobilized ¢brinogen or PAC-1, but
not bind to soluble ¢brinogen when they are stimu-
lated with PMA [9,10]. In platelets, activation of
PAR1 has e¡ects that go beyond activation of
PKC alone (reviewed in [43]) and there was reason
to believe that this is also the case in CHRF-288
cells, where thrombin and SFLLRN were shown to
increase the cytosolic Ca2 concentration [14] and
activate PI 3-kinase [30]. Therefore, we asked ¢rst
whether PAR1 activation would cause CHRF-288
cells to bind to either soluble or immobilized ¢brino-
gen. Second, we asked whether the signalling path-
ways initiated by thrombin and SFLLRN in CHRF-
288 cells were similar to those evoked during platelet
activation and, ¢nally, we asked whether the conse-
quences of outside-in signalling would be the same in
CHRF-288 cells as in platelets, particularly if the
CHRF-288 cells proved to be incapable of binding
soluble ¢brinogen.
The results show that KIIbL3 does not undergo the
conformational change needed to bind to soluble ¢-
brinogen or PAC-1 when CHRF-288 cells are acti-
vated by thrombin or SFLLRN. The cells will, how-
ever, adhere to immobilized ¢brinogen in an KIIbL3-
dependent manner. Adhesion was followed by cell
spreading. These responses apparently require an in-
crease in the cytosolic Ca2 concentration since rais-
ing intracellular Ca2 with an ionophore was su⁄-
cient to cause adhesion and suppressing the
SFLLRN-induced increase in Ca2 with BAPTA in-
hibited adhesion. Notably, although PMA was also
e¡ective in causing the CHRF-288 cells to adhere to
¢brinogen, an inhibitor of PKC activity had no ap-
parent e¡ect on adhesion in response to SFLLRN,
even though it inhibited the same response to PMA.
By extension, this suggests that the Bis-IM-sensitive
isoforms of PKC are not required for the adhesion
caused by PAR1 activation. Other responses to
thrombin and SFLLRN that are known to occur in
platelets and support platelet aggregation, including
activation of phospholipase C, phospholipase A2 and
PI 3-kinase, also occur in CHRF-288 cells ([14,30]
and the present studies) and therefore, do not readily
account for the failure of CHRF-288 cells to bind
soluble ¢brinogen.
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Present theories suggest that the binding of integ-
rins to immobilized ligands do not need to be due to
an increase in a⁄nity, but requires only an increase
in avidity due to the accumulation of weaker inter-
actions between the ligand and multiple copies of the
integrin [11]. This implies an increase in the lateral
mobility of the integrin, allowing it to accumulate at
the interface between the cell and the ligand-coated
surface. Such a redistribution of KIIbL3 has been ob-
served in platelets when they adhere to ¢brinogen
[44]. Studies in lymphocytes have shown that expo-
sure to cytochalasin D increases LFA-1 mobility and
causes the cells to adhere to immobilized ICAM-1 as
e¡ectively as when the cells are incubated with PMA
[24]. We found that cytochalasin D causes CHRF-
288 cells to adhere to ¢brinogen. The extent of ad-
hesion was similar to that seen after incubation with
thrombin or PMA. This is also true in platelets,
where cytochalasin D also causes KIIbL3-mediated
adhesion to ¢brinogen. In addition, Shattil and co-
workers [5] have recently shown that CHO cells ex-
pressing a chimera of KIIbL3 fused to FKBP will ad-
here to immobilized ¢brinogen when exposed to a
cytoplasmic FKBP dimerizing agent. The cells also
bound soluble PAC-1 and ¢brinogen, although with
less e⁄ciency than normally seen in agonist-activated
platelets. This suggests that more than just integrin
clustering is needed for the binding of soluble li-
gands.
In platelets, integrin engagement with soluble ¢bri-
nogen is associated with outside-in signalling. Some
molecules, such as the non-receptor tyrosine kinase
Syk, are activated to a greater extent when platelets
are allowed to aggregate than when they are not
[45,46]. Others, such as FAK, are activated only
when integrin clustering has occurred [11]. Agonist-
independent clustering of KIIbL3 can cause FAK
phosphorylation and Syk activation even in the ab-
sence of adhesion [5]. We ¢nished by asking whether
adhesion of the CHRF-288 cells to ¢brinogen would
initiate integrin-dependent outside-in signalling and,
if so, whether the consequences would be the same as
seen during platelet aggregation. Two established
markers of outside-in signalling were measured,
phosphorylation of FAK and the sustained phos-
phorylation of ERK2. FAK became phosphorylated
when the CHRF-288 cells were incubated with
SFLLRN, but only when they were allowed to ad-
here to ¢brinogen. ERK2, on the other hand, became
phosphorylated even in the absence of adhesion, but
adhesion extended the duration of phosphorylation.
This was in contrast to the phosphorylation of
cPLA2 and release of arachidonate from the cells,
which were una¡ected by adhesion. ERK2 was also
phosphorylated, although minimally, when adhesion
of the CHRF-288 cells was forced by LIBS6 in the
absence of an added agonist.
The ¢ndings with ERK2 resemble those reported
in adherent cells, but contrast with those obtained
when platelets aggregate. Nadal and co-workers
[35] have recently shown that the engagement of
KIIbL3 suppresses rather than promotes ERK2 phos-
phorylation in platelets. They found that ERK2 be-
comes phosphorylated to a greater extent in throm-
basthenic platelets, which lack KIIbL3, than in normal
platelets. From this, they concluded that outside-in
signalling through KIIbL3 in platelets has a negative
e¡ect on MAPK regulation. This would be consistent
with an earlier ¢nding by Papko¡ et al. [36] who
observed an increased activity of a MAPK substrate,
ribosomal S6 kinase, in response to thrombin in the
presence of RGDS.
In summary, the present studies on CHRF-288
cells extend previous work on the interaction of
KIIbL3 with ¢brinogen on megakaryoblastic cell
lines and transfected cells by showing that (1) acti-
vation of CHRF-288 cells via a G protein-coupled
receptor can initiate KIIbL3-dependent adhesion, even
if it does not promote the conformational switch
required to bind soluble ¢brinogen, (2) this response
depends on an increase in the cytosolic Ca2 concen-
tration, but may not absolutely require PKC or PI
3-kinase, (3) the interaction of CHRF-288 cells with
immobilized ¢brinogen is su⁄cient to support out-
side-in signalling within the cells, although the pat-
tern of outside-in signalling events that was observed
is di¡erent than that observed during platelet aggre-
gation, and (4) crosstalk from outside-in signalling
pathways can reinforce downstream events from ac-
tivated PAR1 in CHRF-288 cells, including the acti-
vation of at least one form of MAPK. However, it
appears to do so in a manner that is distinct from
that in platelets, which suggests that the failure to
form high a⁄nity KIIbL3-¢brinogen complexes may
in£uence the repertoire of outside-in signals that
can occur.
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